证券简称：尖峰集团 证券代码：600668 编号：临 2025-037 浙江尖峰集团股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 回购方案首次披露日 | 2025年4月22日 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过本次回购股份方案之日起12个月内 | | 预计回购金额 | 2,000万元-4,000万元 | | 回购用途 | □减少注册资本 | | | √用于员工持股计划或股权激励 | | | □用于转换公司发行的可转换为股票的公司债券 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 0股 | | 累计已回购股数占总股本比例 | 0.00% | | 累计已回购金额 | 0.00元 | | 实际回购价格区间 / | | 重要内容提示： 一、回购股份的基本情况 浙江尖峰集团股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召开 了第十二届董事会第 7 次会议，审议通过了《关于以集中竞价交易 ...

证券代码：600668 证券简称：尖峰集团 编号：临 2025-036 浙江尖峰集团股份有限公司 关于子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 风险提示：由于医药产品具有高科技、高风险、高附加值的特点，不仅 药品的前期研发及研制、报批到投产的周期长、投入大、环节多，而且药品的生 产和销售也容易受到国家政策、市场环境变化等因素影响，具有较大不确定性。 敬请广大投资者注意投资风险。 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的下属子公司安徽 尖峰北卡药业有限公司（以下简称"尖峰北卡"）收到国家药品监督管理局关于化 学原料药磷酸特地唑胺的《化学原料药上市申请批准通知书》（通知书编号： 2025YS00633），现将相关情况公告如下： 一、化学原料药的基本情况 化学原料药名称：磷酸特地唑胺 包装规格：5kg/桶、10kg/桶、20kg/桶 通知书编号：2025YS00633 化学原料药注册标准编号：YBY67532025 生产企业名称：安徽尖峰北卡药业有限公司 生产企 ...

尖峰北卡已具备相应的生产线，本次获得化学原料药磷酸特地唑胺的《化学原料药上市申请批准通知 书》，表明该原料药已符合国家相关原料药审评技术标准，可在国内市场进行销售，有助于拓展子公司 的业务领域。 尖峰集团（600668）(600668.SH)发布公告，近日，公司的下属子公司安徽尖峰北卡药业有限公司(以下 简称"尖峰北卡")收到国家药品监督管理局关于化学原料药磷酸特地唑胺的《化学原料药上市申请批准 通知书》。 ...

每经AI快讯，7月30日，尖峰集团（600668）(600668.SH)公告称，公司下属子公司安徽尖峰北卡药业有 限公司收到国家药品监督管理局关于化学原料药磷酸特地唑胺的《化学原料药上市申请批准通知书》。 磷酸特地唑胺是由Cubist Pharmaceuticals公司研发的新型抗细菌感染用药，尖峰北卡已具备相应的生产 线，该批准表明该原料药已符合国家相关原料药审评技术标准，可在国内市场进行销售，有助于拓展子 公司的业务领域。 ...

人民财讯7月30日电，尖峰集团（600668）7月30日晚间公告，近日，公司下属子公司尖峰北卡收到国家 药品监督管理局关于化学原料药磷酸特地唑胺的《化学原料药上市申请批准通知书》。磷酸特地唑胺是 由Cubist Pharmaceuticals公司研发的新型抗细菌感染用药。 ...

Group 1 - The core announcement is that Zhejiang Jianfeng Group's subsidiary, Jianfeng Pharmaceutical, has received the approval notice for the listing application of the chemical raw material drug, Empagliflozin, from the National Medical Products Administration [1][2] - Empagliflozin is classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, which aids in blood sugar control for adult patients with type II diabetes by blocking glucose reabsorption in the kidneys [2] - The total investment in the research and development of the Empagliflozin raw material project is approximately RMB 8.8769 million [2] Group 2 - The approval indicates that the raw material drug meets the national technical standards for raw material drug review, allowing it to be sold in the domestic market, which will help expand the subsidiary's business scope [3] - The approval notice is valid until July 24, 2030, and the production facility is located in Jinhua City, Zhejiang Province [2]

证券代码：600668 证券简称：尖峰集团 编号：临 2025-035 浙江尖峰集团股份有限公司 关于子公司获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 近日，浙江尖峰集团股份有限公司（以下简称"本公司"）的全资子公司浙江 尖峰药业有限公司（以下简称"尖峰药业"）收到国家药品监督管理局关于化学原 料药恩格列净的《化学原料药上市申请批准通知书》（通知书编号：2025YS00624）， 现将相关情况公告如下： 一、化学原料药的基本情况 化学原料药名称：恩格列净 包装规格：10kg/桶 通知书编号：2025YS00624 化学原料药注册标准编号：YBY66992025 生产企业名称：浙江尖峰药业有限公司 生产企业地址：浙江省金华市婺城区白汤下线高畈段 58 号 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 1 本次尖峰药业获得化学原料药恩格列净的《化学原料药上市申请批准通 知书》，表明该原料药已符合国家相关原料药审评技术标准，可在国内 市场进行销售 ...

【环球网财经综合报道】一场针对行业"内卷"的治理正在中国多个传统产业掀起波澜。自今年政策层面密集发声整治"内卷式"竞争以来，工业和信息化部近 期更是明确将实施新一轮钢铁、有色金属、石化、建材等十大重点行业稳增长工作方案，为推动行业调结构、优供给、淘汰落后产能。光伏、水泥、钢铁等 行业已率先响应，减产行动迅速展开。 " 反内卷 " 行动带来结构性机遇 政策发力去产能、优结构，正为相关行业带来新的发展契机。传统的基建行业如钢铁、有色金属和建材，正成为机构看好的投资"洼地"。政策旨在清除无效 供给，提升行业集中度，这预示着优质企业将迎来更好的发展环境。 部分已盈利的公司今年上半年业绩更上一层楼，三和管桩、万年青、北方稀土等净利润同比预增幅度居前。三和管桩净利润预计同比增长高达30.91倍至 38.89倍，主要得益于产品矩阵丰富、成本管控优化和产品结构改善。 市场资金加速流入 业绩的改善直接点燃了市场热情。数据显示，上述68只业绩预增的基建股在7月平均上涨15.82%，其中柳钢股份、盛和资源、华新水泥、三和管桩、中材科 技、北方稀土累计涨幅均超40%，柳钢股份更是以121.31%的累计涨幅高居榜首。 从估值角度看，截 ...

Group 1 - The Yarlung Tsangpo River downstream hydropower project has officially commenced with a total investment of approximately 1.2 trillion yuan, aiming to build five tiered power stations primarily for electricity transmission and local consumption in Tibet [1] - The Ministry of Industry and Information Technology (MIIT) plans to accelerate the development of biomanufacturing and low-altitude industries, while promoting innovation in future industries such as humanoid robots and brain-computer interfaces [2][3] - The MIIT and the National Development and Reform Commission (NDRC) are set to issue work plans to stabilize growth in key industries including steel, non-ferrous metals, petrochemicals, and building materials [2][3] Group 2 - The U.S. Department of Commerce has imposed a preliminary anti-dumping duty of 93.5% on Chinese imported anode-grade graphite, citing unfair subsidies [5] - The State Administration for Market Regulation has urged major platform companies like Ele.me, Meituan, and JD.com to standardize promotional activities and foster a healthy competitive environment in the food service industry [6] - A meeting was held to discuss the regulation of the new energy vehicle industry, focusing on enhancing supervision and monitoring product prices and quality [8] Group 3 - The China Iron and Steel Association has proposed a new mechanism for capacity governance to prevent overcapacity risks in the steel industry and to eliminate irrational competition [10] - Yu Shu Technology has initiated its listing guidance, with its controlling shareholder holding approximately 34.76% of the company's shares [11] - Multiple provinces are planning to establish companies to develop local cultural creative Moutai liquor, with participation from distributors based on their allocation of Moutai products [12] Group 4 - As of July 18, 1551 A-share listed companies have released performance forecasts for the first half of 2025, with 26 companies expecting a net profit increase of over 1000% year-on-year [14] - Longhua Automobile reported a net profit of 6.337 billion yuan for the first half of the year, reflecting a year-on-year decline of 10.22% [19] - The major shareholder of Hongbaoli plans to reduce its stake by up to 2% [20]

Core Viewpoint - The company has announced an adjustment to the maximum repurchase price of its shares following the implementation of the 2024 annual equity distribution, reducing it from RMB 15.00 per share to RMB 12.42 per share, effective from July 15, 2025 [1][2]. Group 1: Share Repurchase Plan - The company plans to repurchase shares using its own and raised funds through centralized bidding, with a total expected repurchase amount of no less than RMB 20 million [1][2]. - The maximum repurchase price was initially set at RMB 15.00 per share but has been adjusted to RMB 12.42 per share due to the distribution of cash dividends and capital reserve conversion [2][3]. - The repurchase will be based on the total share capital minus the shares held in the repurchase account, with a cash dividend of RMB 0.1 per share and a capital reserve conversion of 0.2 shares per share [2]. Group 2: Adjustment Calculation - The adjusted maximum repurchase price is calculated as follows: (15.00 - 0.1) ÷ (1 + 0.2) ≈ 12.42 RMB per share [2]. - The expected maximum number of shares to be repurchased is approximately 1.61 million shares, representing 0.39% of the company's current total share capital [2]. Group 3: Compliance and Disclosure - The company will adhere to relevant regulations and guidelines during the repurchase process and will disclose information regarding the progress of the repurchase in a timely manner [3].